Unlocking TAS2R14 activation through intricate multi-ligand binding networks

Xiaolong Hu, Weizhen Ao, Mingxin Gao, Lijie Wu, Yuan Pei, Shenhui Liu, Qianqian Sun, Junlin Liu, Longquan Jiang, Yiran Wu, Xin Wang, Yan Li, Qiwen Tan, J. L. Cheng, Fan Yang, Chi Yang, Jin‐Peng Sun, Hua Tian, Zhi‐Jie LiubioRxiv 2024 · DOI

Abstract

Bitter taste receptors, particularly TAS2R14, play central roles in discerning a wide array of bitter substances, ranging from dietary components to pharmaceutical agents. Beyond the tongue, TAS2R14 is broadly expressed in non-gustatory tissues, suggesting significant physiological roles and therapeutic potential. This study presents cryo-electron microscopy (cryo-EM) structures of TAS2R14 in complex with agonists flufenamic acid (FFA) and aristolochic acid (AA), coupled with G protein subtypes gustducin and $G_{i1}$. Distinct from most known G protein-coupled receptors (GPCRs), TAS2R14 agonists bind to multiple intracellular pockets. We highlight cholesterol molecules occupying an upper transmembrane site—typically the orthosteric pocket in other GPCRs—and the entrance to an intracellular agonist-binding pocket, suggesting an endogenous modulatory function. Structural and mutagenesis analyses illuminate the receptor’s broad-spectrum ligand recognition and activation via intricate multiple ligand-binding sites. Furthermore, we unveil the structural configuration of gustducin and its interaction with TAS2R14, as well as the coupling mode of $G_{i1}$. This investigation is instrumental in advancing our knowledge of the mechanisms underlying bitter taste recognition and response, with broader relevance to sensory biology and pharmacology.

Introduction: The "Swiss Army Knife" of Taste

Humans possess 25 different TAS2R receptors, but TAS2R14 stands out for its exceptional promiscuity. It is capable of responding to over 150 diverse compounds, including clinical drugs and plant-derived toxins. Its significance extends far beyond the gustatory system; TAS2R14 is expressed in the heart and lungs, where it serves as a potential therapeutic target. In airway smooth muscle, for instance, its activation facilitates bronchodilation, making it a primary candidate for treating asthma and Chronic Obstructive Pulmonary Disease (COPD).

Despite its pharmacological importance, the structural mechanisms governing how TAS2R14 recognizes such a vast array of chemical shapes remained elusive. Specifically, the location of the orthosteric binding site and the transition from an inactive to an active signaling state were unknown. This research utilizes high-resolution cryo-EM to map the structural "blueprints" of TAS2R14, revealing a unique activation mechanism that deviates from the standard GPCR paradigm.

Methods and Structural Determination

To capture the receptor in its active state, the researchers employed cryo-electron microscopy (cryo-EM). Given the inherent instability of the receptor, the team utilized the NanoBiT strategy, fusing components of the receptor to G protein subunits to stabilize the complex.

The study focused on TAS2R14 bound to two potent agonists:

  1. Flufenamic acid (FFA): A non-steroidal anti-inflammatory drug.
  2. Aristolochic acid (AA): A plant-derived nephrotoxin.

These complexes were solved in conjunction with both the "native" taste transducer, gustducin, and the common signaling protein $G_{i1}$. The resulting maps reached global resolutions between 2.7 Å and 3.3 Å, providing sufficient detail to observe individual water molecules and the precise orientation of ligands. These structural findings were further validated through site-directed mutagenesis and functional assays, including calcium mobilization and BRET (Bioluminescence Resonance Energy Transfer).

Key Insights: An Intracellular Paradigm Shift

The Intracellular Agonist Pocket

In the vast majority of GPCRs, ligands bind to an extracellular pocket. However, TAS2R14 breaks this rule. The agonists AA and FFA were found to bind in Pocket-2, located in the intracellular half of the receptor. This unconventional location suggests that bitter substances must either cross the cell membrane or enter the receptor via the lipid bilayer to trigger a response.

Cholesterol as a Gatekeeper

The site traditionally used for ligand binding in other GPCRs (Pocket-1) is instead occupied by a cholesterol molecule in TAS2R14. This cholesterol appears to act as an endogenous "volume knob," stabilizing the receptor's architecture and modulating its sensitivity to bitter compounds. This suggests that the lipid environment of the cell membrane plays a direct role in how we perceive bitterness.

The TM6 "Zipper" Mechanism

The research identified that Transmembrane Helix 6 (TM6) is highly dynamic. In the inactive (apo) state, this region is disordered. Upon agonist binding in the internal pockets, TM6 "zips" into a structured conformation, sealing the ligand inside and creating the necessary interface for G protein coupling. This structural transition is the physical trigger for cellular signaling.

Multi-Ligand Binding Networks

The study also identified a Pocket-3 at the base of the receptor. Here, AA can wedge itself between the receptor and the G protein. This suggests a complex regulatory network where multiple ligands—or multiple molecules of the same ligand—can bind simultaneously to fine-tune the receptor's activity through allosteric modulation.

Functional Validation and Versatility

Mutagenesis confirmed the importance of the structural findings. Altering specific residues in Pocket-2, such as H276 and Y107, completely abolished the receptor's response to bitter compounds, proving that this internal site is the primary trigger for activation.

Furthermore, the study explains TAS2R14's versatility. The receptor interacts with gustducin and $G_i$ in nearly identical ways, allowing it to function effectively in both the mouth (signaling taste) and the lungs (signaling bronchodilation). The presence of specific residues like G104 and G229 provides the internal volume and flexibility required to accommodate a wide variety of chemical structures, explaining the receptor's broad-spectrum sensitivity.

Conclusion and Future Directions

This structural mapping of TAS2R14 provides a vital framework for sensory biology and drug discovery. However, the discovery of the intracellular binding site introduces new challenges for pharmacology. Future drugs targeting TAS2R14 for respiratory conditions must be designed with the chemical properties necessary to penetrate the cell membrane or the lipid bilayer to reach their target. Additionally, while the role of Pocket-3 remains to be fully elucidated, it opens the door for developing allosteric modulators that could precisely control bitter taste perception or therapeutic signaling without fully activating or blocking the receptor.

Summary updated

Abstract

Abstract Bitter taste receptors, particularly TAS2R14, play central roles in discerning a wide array of bitter substances, ranging from dietary components to pharmaceutical agents 1–3 . In addition, TAS2R14 has broad expression in non-gustatory tissues, suggesting its important roles in selective physiological processes and therapeutic potential 4 . Here, we present cryo-electron microcopy structures of TAS2R14 in complex with flufenamic acid and aristolochic acid, coupling with G protein subtypes gustducin and G i . Distinct from most known GPCRs, agonists of TAS2R14 bind to multiple intracellular pockets. We highlight the cholesterol molecules occupying an upper transmembrane site, typically the orthosteric pocket in other GPCRs, also binding in the entrance to an intracellular agonist binding pocket, suggesting an endogenous modulatory function 5 . The structural and mutagenesis analysis illuminate the receptor’s broad-spectrum ligand recognition and activation via intricate multiple ligand-binding sites. Furthermore, we unveil the structural configuration of gustducin and its interaction with TAS2R14, as well as the coupling mode of G i1 . This investigation should be instrumental in advancing our knowledge of the mechanisms underlying bitter taste recognition and response, with broader relevance to sensory biology and pharmacology.
BibTeX
@misc{hu2024unlocking,
  author = {Xiaolong Hu and Weizhen Ao and Mingxin Gao and Lijie Wu and Yuan Pei and Shenhui Liu and Qianqian Sun and Junlin Liu and Longquan Jiang and Yiran Wu and Xin Wang and Yan Li and Qiwen Tan and J. L. Cheng and Fan Yang and Chi Yang and Jin‐Peng Sun and Hua Tian and Zhi‐Jie Liu},
  title = {{Unlocking TAS2R14 activation through intricate multi-ligand binding networks}},
  year = {2024},
  doi = {10.1101/2024.04.13.589249},
  howpublished = {bioRxiv},
}
Figure